Home > Business News > Article
Tuesday January 6, 02:56 PM Source: Financial Express

Aurobindo gets Canada's nod for epilepsy drug

Drug maker Aurobindo Pharma (AUROPHARM.NS : 818.4 +11.9) on Tuesday said that it has received regulatory approval from Canada for a drug used in epilepsy.

In a filing to the Bombay Stock Exchange (^BSESN : 16158.28 +94.38), Aurobindo Pharma informed that its has received approval from federal department Health Canada for Gabapentin capsules.

The drug is in the strengths of 100mg, 300mg and 400 mg, the filing added.

Gabapentin capsules is the generic equivalent of Pfizer Canada Inc's Neurotinl capsules of same strength, falls under the central nervous system segment and is indicated for treatment of seizures in patients diagnosed with epilepsy, it added.

Further, this is company's sixth product approval from Health Canada.

Health Canada is the federal department responsible for helping Canadians maintain and improve their health.

Email to friend | IM to friend

RECENT BUSINESS NEWS

>> More News

RELATED NEWS

RSS FEEDS

All headlines to your personalized My Yahoo! page
(Learn about My Yahoo! and RSS)
  • All Business News
  • India Business News
  • World Business News
  • Personal Finance News
More Finance RSS Feeds

  • Cricket

    One of my best knocks
    Batting maestro Sachin Tendulkar rated his 175 against Australia on Thursday as one of the best knoc... » More

  • Movies

    'Avatar' at $230 million
    James Cameron's comeback directorial venture 'Avatar' is being touted as the most expensive film eve... » More

  • Lifestyle

    Pakistan goes chic
    Moving beyond the burqa, models in elegant designs sent a strong message to hardliners during the Pa... » More



Quotes delayed, except where indicated otherwise.
Delay times are 15 mins for BSE and NSE(when not logged-in) See also delay times for other exchanges.

All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Prior to execution of any security trade, you are advised to consult your authorized financial advisor to verify the accuracy of all information. Neither Yahoo! nor any independent provider is liable for any informational errors, incompleteness or delays or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found herein.